Nivolumab Associated With Higher Survival in Pediatric Advanced-Stage Hodgkin Lymphoma
Replacing brentuximab vedotin with nivolumab in first-line treatment combined with the chemotherapy regimen AVD improved progression-free survival in pediatric patients with newly diagnosed, advanced-stage classic Hodgkin lymphoma (cHL).
ความคิดเห็น